SCHEMBL335272

SCHEMBL335272

CCOC(=O)c1cn(CC)c2c(O)cccc2c1=O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.70
LMNA P02545 3/20 0.55
CLEC4M Q9H2X3 1/20 0.48
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA7 P43166 1/20 0.48
CA9 Q16790 1/20 0.48
CA14 Q9ULX7 1/20 0.48
KDM4E B2RXH2 3/20 0.47
ALDH1A1 P00352 2/20 0.47
HTT P42858 2/20 0.47
CYP1A2 P05177 1/20 0.47
TSHR P16473 2/20 0.47
POLB P06746 1/20 0.47
MAPK1 P28482 1/20 0.47
CDC25B P30305 1/20 0.46
MAOB P27338 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
MEN1 O00255 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14845110 0.85 TDP1 (0.67) TDP1LMNAKDM4EALDH1A1HTT
SCHEMBL11405256 0.84 LMNA (0.51) TDP1LMNAKDM4EALDH1A1HTT
SCHEMBL7283936 0.81 TDP1 (0.68) TDP1LMNAKDM4EALDH1A1HTT
SCHEMBL7056985 0.80 LMNA (0.69) TDP1LMNAKDM4EALDH1A1HTT
SCHEMBL336103 0.79 TDP1 (0.63) TDP1LMNAKDM4EALDH1A1HTT
SCHEMBL335844 0.79 TDP1 (0.59) TDP1LMNACLEC4MKDM4EALDH1A1
SCHEMBL8165400 0.79 TDP1 (0.65) TDP1LMNAKDM4EALDH1A1HTT
SCHEMBL15999535 0.78 TDP1 (0.64) TDP1LMNAKDM4EALDH1A1HTT
SCHEMBL9148015 0.77 TDP1 (0.63) TDP1LMNAKDM4EALDH1A1HTT
SCHEMBL7292583 0.77 TDP1 (0.63) TDP1LMNAKDM4EALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
EP-1985620-A1 10a-AZALIDE COMPOUND TAISHO PHARMACEUTICAL CO., LTD (JP) 2008-10-29 EP disclosed
WO-2004101589-A1 NOVEL 14 AND 15 MEMBERED-RING COMPOUNDS GLAXO GROUP LIMITED (GB) 2004-11-25 WO disclosed
WO-2004101584-A1 MACROLIDES SUBSTITUTED AT THE 3-POSITION HAVING ANTIMICROBIAL ACTIVITY GLAXO GROUP LIMITED (GB) 2004-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 TDP1 2672/4885LMNA 1467/4885CLEC4M 2973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.